Quick Answer
Monte Rosa Therapeutics, Inc. reported Operating Income of -$54.21 million for fiscal year 2025.
Monte Rosa Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$54.21M | +33.2% |
| 2024 | -$81.11M | +43.4% |
| 2023 | -$143.31M | -27.5% |
| 2022 | -$112.38M | -54.2% |
| 2021 | -$72.88M | -160.2% |
| 2020 | -$28.01M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$32.98M | -24.3% | -112.0% |
| June 30, 2025 | -$15.55M | +52.3% | -135.3% |
| March 31, 2025 | $44.04M | +226.0% | +266.0% |
| September 30, 2024 | -$26.53M | +28.2% | +18.7% |
| June 30, 2024 | -$32.64M | +12.3% | +6.6% |
| March 31, 2024 | -$34.95M | -2.0% | +5.5% |
| September 30, 2023 | -$36.97M | -30.3% | +0.7% |
| June 30, 2023 | -$37.22M | -36.7% | -8.6% |
- Monte Rosa Therapeutics, Inc. showed an increase of +33.2% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Monte Rosa Therapeutics, Inc.’s operating income has declined by 93.5% (from -$28.01 million to -$54.21 million).
- The most recent figure is from Monte Rosa Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: